- Your cart is empty
- Continue Shopping
Waklert vs Artvigil: What Is the Difference?
- Armodafinil
- Posted on
-
by ModvigilAUS Medical Editorial Team
- 0 comments
Medical Disclaimer
This article provides general educational information only and is not medical advice. Armodafinil is a Schedule 4 prescription-only medicine in Australia. Consult a qualified healthcare professional about diagnosis, treatment, medicine interactions and safety. Overseas availability does not establish Australian ARTG registration.
In a Waklert vs Artvigil comparison, the two overseas medicine brands that list armodafinil as their active ingredient. Both have 150 mg tablet presentations, but sharing an active ingredient does not automatically mean the products have identical formulations, clinical effects or regulatory approvals.
The main difference between Waklert and Artvigil is their brand identity and associated pharmaceutical companies. Waklert appears in Sun Pharmaceutical Industries’ Indian product catalogue, while Artvigil appears in HAB Pharmaceuticals’ product catalogue. For a related educational comparison of different active ingredients, see Modvigil vs Waklert, which discusses modafinil and armodafinil rather than two armodafinil brands.
In the Waklert vs Artvigil evidence review, there is insufficient publicly verified comparative clinical evidence to conclude that one brand works better, lasts longer or causes fewer side effects than the other.
For Australian readers, another important distinction is regulatory status. See our medical disclaimer for further context. Armodafinil is a prescription-only medicine, and the Australian registration of Nuvigil does not extend automatically to either Waklert or Artvigil.
This Waklert vs Artvigil comparison examines what is documented, what remains uncertain and why those differences matter when discussing armodafinil treatment with a healthcare professional.
Waklert vs Artvigil: The Main Differences
The Waklert vs Artvigil comparison begins with their labelled ingredients: both brands are associated with armodafinil tablets, but they have different product identities.
The following comparison separates verified information from details that require additional product-specific evidence.
| Feature | Waklert | Artvigil |
|---|---|---|
| Product identity | Overseas armodafinil brand | Overseas armodafinil brand |
| Active ingredient | Armodafinil | Armodafinil |
| Documented 150 mg presentation | 150 mg tablet | 150 mg tablet |
| Company association | Listed by Sun Pharmaceutical Industries | Listed by HAB Pharmaceuticals |
| Medicine form | Oral tablet | Oral tablet |
| Complete inactive ingredient formulation | Not established in this comparison | Not established in this comparison |
| Direct comparative clinical evidence | No reliable head-to-head evidence identified | No reliable head-to-head evidence identified |
| Australian registration | Historical TGA evidence of non-inclusion; current status not conclusively established | Current ARTG registration not established in this review |
| Australian prescription status | Armodafinil is Schedule 4 | Armodafinil is Schedule 4 |
In the Waklert vs Artvigil comparison, the documented similarities are straightforward. Both product catalogues identify armodafinil as the active ingredient and list a 150 mg tablet presentation.
The unresolved differences are equally important.
For Waklert vs Artvigil, the available product listings do not provide sufficient comparative information about excipients, manufacturing specifications, dissolution characteristics or bioequivalence.
Consequently, the Waklert vs Artvigil evidence does not justify a claim of identical performance nor a claim that one product is clinically superior can be justified from the information reviewed.
Why Can Formulation Differences Matter?
A medicine contains more than its active pharmaceutical ingredient.
Tablets may also contain inactive ingredients, known as excipients, which help determine the tablet’s physical structure, stability and manufacture.
Different products containing the same active ingredient can have different excipient formulations. However, this does not necessarily mean they produce clinically meaningful differences.
A reliable comparison would require verified formulation information and, where appropriate, comparative pharmaceutical or pharmacokinetic testing.
Without that evidence, claims that Waklert absorbs faster or Artvigil produces smoother effects remain unsubstantiated.
Do Waklert and Artvigil Contain the Same Active Ingredient?
Yes. The companies’ published product catalogues identify armodafinil as the active ingredient in both Waklert 150 mg and Artvigil 150 mg tablets.
Armodafinil is the active pharmaceutical ingredient. Waklert and Artvigil are branded products associated with that ingredient.
Armodafinil is the R-enantiomer of modafinil. An enantiomer is one of two molecular forms that have the same chemical composition but different three-dimensional arrangements.
That distinction is relevant to armodafinil’s pharmacological properties, although it does not establish a clinical difference between Waklert and Artvigil.
For a labelled 150 mg presentation, each brand specifies the same amount of armodafinil per tablet.
However, identical labelled strength does not independently establish that different products have equivalent bioavailability, identical quality characteristics or interchangeable clinical performance.
Those conclusions require appropriate product-specific evidence.
How Does Armodafinil Work?
Armodafinil is a wakefulness-promoting medicine that acts on the central nervous system.
Its precise mechanism of action is not fully understood. Clinical pharmacology research shows that armodafinil interacts with the dopamine transporter and inhibits dopamine reuptake, contributing to its wakefulness-promoting activity.
In Australia, registered armodafinil medicines such as Nuvigil have approved indications involving excessive sleepiness associated with narcolepsy, certain cases of obstructive sleep apnoea and shift work sleep disorder.
These are medically assessed conditions, not general indications for increasing everyday productivity.
Because Waklert and Artvigil both identify armodafinil as their active ingredient, the established pharmacology of armodafinil provides relevant background for understanding them.
However, the mechanism of the ingredient cannot establish that the two finished products have identical onset, duration or clinical effects.
Can Their Effects or Side Effects Be Different?
It is possible for different formulations containing the same active ingredient to have different pharmaceutical characteristics.
Whether such differences produce meaningful clinical effects must be demonstrated rather than assumed.
For Waklert and Artvigil specifically, there is insufficient verified comparative evidence to establish consistent differences in effectiveness, duration or adverse reaction rates.
Effects and Duration
Armodafinil promotes wakefulness, but the clinical response to treatment varies between individuals.
Factors such as underlying sleep disorders, other medicines, liver function and individual pharmacokinetics may influence treatment response.
The Australian Nuvigil Product Information provides clinical information about armodafinil’s absorption and elimination. However, those findings do not support a conclusion that Waklert consistently lasts longer than Artvigil, or vice versa.
A product’s stated strength alone also cannot predict how long its effects will last in an individual.
Potential Side Effects
Clinical studies of armodafinil have documented adverse reactions including:
- Headache
- Nausea
- Dizziness
- Insomnia
- Anxiety
- Reduced appetite
More serious risks include severe skin reactions, allergic reactions, psychiatric symptoms and cardiovascular concerns.
These are established armodafinil safety considerations, not evidence that Waklert and Artvigil have identical side-effect frequencies.
Neither brand should be described as safer without reliable comparative clinical evidence.
Persistent or concerning symptoms warrant professional medical assessment.
What Does the Available Clinical Evidence Show?
A useful Waklert versus Artvigil comparison must distinguish evidence about the active ingredient from evidence about the individual products.
Evidence for Armodafinil
Armodafinil has been investigated in controlled clinical studies involving excessive sleepiness associated with recognised sleep disorders.
The Australian Nuvigil prescribing information, revised 23 April 2026, summarises clinical evidence supporting its registered indications and documents known adverse reactions, precautions and pharmacological characteristics.
This evidence helps healthcare professionals understand armodafinil as a medicine.
It does not establish that every overseas armodafinil product has undergone the same regulatory assessment or clinical testing.
Evidence Comparing Waklert and Artvigil
No reliable published head-to-head clinical trial directly comparing Waklert with Artvigil was identified in the evidence reviewed for this article.
Similarly, publicly verifiable product-specific bioequivalence evidence sufficient to establish clinical interchangeability was not identified.
A head-to-head study would directly assess the two products under a defined research protocol. A bioequivalence study would investigate whether the products deliver comparable exposure to the active ingredient under specified conditions.
Without suitable evidence, several questions remain unresolved:
- Do the products have identical excipient formulations?
- Are their dissolution and absorption characteristics comparable?
- Has bioequivalence been demonstrated?
- Are there clinically meaningful differences in adverse reaction rates?
The absence of accessible comparative evidence does not prove that the products differ clinically. It means the comparison cannot reliably establish equivalence or superiority.
Are Waklert and Artvigil Registered in Australia?
Australian medicine regulation distinguishes the active ingredient from the individual branded product.
The Therapeutic Goods Administration (TGA) regulates therapeutic goods, while the Australian Register of Therapeutic Goods (ARTG) records products authorised for Australian supply.
Armodafinil Prescription Requirements
Armodafinil is classified as a Schedule 4 (S4) prescription-only medicine in Australia.
This classification applies to the substance regardless of whether an overseas product is labelled Waklert or Artvigil.
Australian supply and importation are subject to applicable legal requirements. An overseas brand’s availability or registration in another country does not establish Australian approval.
What About Nuvigil?
Nuvigil is an Australian-registered medicine containing armodafinil.
Its 150 mg tablet presentation is identified under ARTG number AUST R 226559.
Nuvigil provides an Australian regulatory and clinical reference for armodafinil. However, Nuvigil’s registration, Product Information and quality assessment are specific to that registered product.
They cannot be transferred automatically to Waklert or Artvigil.
Waklert and Artvigil's Australian Status
On 3 June 2021, the TGA reported an enforcement matter involving Waklert-branded tablets that were not included in the ARTG at that time.
This is documented historical information rather than conclusive evidence about the brand’s current registration status.
For Artvigil, a current Australian ARTG registration was not established from the sources reviewed for this article.
Neither brand should be represented as Australian-registered without confirmation of a valid product-specific ARTG entry.
Medicine registration must be verified using the current official register before making a definitive claim about current product-specific status.
Safety Considerations Before Discussing Either Medicine With a Doctor
The most important clinical question is not which brand appears preferable, but whether armodafinil treatment is medically appropriate for the individual.
A healthcare professional should consider the person’s diagnosis, medical history, current medicines and potential treatment risks.
Several issues are particularly relevant.
Existing medical conditions: Cardiovascular disease, high blood pressure, psychiatric conditions and liver impairment may require additional assessment.
Medicine interactions: Armodafinil can interact with other medicines, including hormonal contraceptives and certain medicines used for epilepsy, psychiatric conditions or other medical conditions.
Pregnancy: Australian Nuvigil Product Information states that armodafinil is contraindicated during pregnancy because of reproductive safety concerns. Effective contraception is advised during treatment and for one month after discontinuation. For people using steroidal contraceptives, including certain hormonal contraceptives, an alternative or additional contraceptive method is required during treatment and for two months after discontinuation, because their effectiveness may be reduced.
Sleep-related concerns: Armodafinil does not replace adequate sleep or treatment directed at an underlying sleep disorder. Persistent sleepiness or insomnia should be assessed clinically.
Serious adverse reactions: A new suspected medicine-related rash, mouth sores, facial swelling or other signs of hypersensitivity require immediate medical advice. Breathing difficulty or throat swelling requires emergency assistance.
Product-specific ingredient information also matters when assessing possible allergies or sensitivities.
Patients should not independently substitute one branded prescription medicine for another or adjust their prescribed treatment based on online comparisons.
Frequently Asked Questions
They are different branded products whose 150 mg presentations both list armodafinil as the active ingredient. They should not be regarded as identical finished medicines without appropriate formulation and equivalence evidence.
There is insufficient reliable comparative evidence to conclude that Waklert is stronger than Artvigil. Both brands list a 150 mg armodafinil tablet, but labelled strength does not prove identical clinical performance or establish superiority.
Both involve the same labelled active ingredient, so established armodafinil safety warnings are relevant to each. However, Waklert-specific and Artvigil-specific adverse reaction frequencies have not been established through verified comparative studies.
Clinical interchangeability should not be assumed simply because two products contain the same active ingredient and labelled strength. Any treatment substitution requires appropriate professional assessment and consideration of the specific product.
Nuvigil is an Australian-registered armodafinil medicine. Waklert was identified by the TGA as not included in the ARTG in a 2021 enforcement matter. A current Artvigil registration was not established in this review. Both brands require product-specific verification against the current ARTG.
Conclusion
The main documented similarity in the Waklert vs Artvigil comparison is their labelled active ingredient, armodafinil. Both brands have 150 mg tablet presentations and are associated with different pharmaceutical companies.
In Waklert vs Artvigil, sharing the same ingredient does not demonstrate identical formulations, bioequivalence, treatment duration or side-effect rates.
The available clinical literature primarily supports understanding armodafinil as an active medicine rather than establishing direct differences between these two brands.
For Australian readers, Schedule 4 requirements and individual ARTG registration remain important considerations. Nuvigil’s Australian registration does not establish approval for Waklert or Artvigil.
Any treatment decision or potential substitution should be assessed by an appropriately qualified healthcare professional using reliable product information and the individual’s medical circumstances.
ModvigilAUS Medical Editorial Team
ModvigilAUS Health Research Desk is the internal editorial team behind ModvigilAUS.com's educational content on Modafinil and Armodafinil. All articles are prepared using publicly available medical and scientific references, Australian regulatory guidance, and internal editorial review standards.
See all author post